Skip to main content
SpringerLink
Log in

The cost utility of pemetrexed as first-line therapy for advanced non-small cell lung cancer appears to be hindered by poor basal QOL

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Pinto CG, Manacas M, Miguel LS.Cost-effectiveness of Pemetrexed in First Line Treatment of Non-small Cell Lung Cancer in Portugal. 12th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research: (plus oral presentation) abstr. CN4, 24 Oct 2009. Available from: URL: http://www.ispor.org/Events/Index.aspx?eventId=30

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

The cost utility of pemetrexed as first-line therapy for advanced non-small cell lung cancer appears to be hindered by poor basal QOL. Pharmacoecon. Outcomes News 591, 8 (2009). https://doi.org/10.2165/00151234-200905910-00015

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00151234-200905910-00015

Keywords

Search

Navigation